Clinical Trial Update: A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial of oral tazemetostat for relapsed/refractory follicular lymphoma without EZH2 gain-of-function mutation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Tazemetostat (tazemetostat)

Snippet

Sponsor: Epizyme, Inc. | Conditions: Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | Status: WITHDRAWN